Skip to content
Screener

Veracyte VCYT Q4 2025 Annual earnings

Reported February 25, 2026 · After market close

Revenue$140.6MBeat by $4.8M
EPS$0.53Beat by $0.12
Revenue estimate$135.8M
EPS estimate$0.41

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$147.2M
EPS estimate$0.43

Financials

Q4 2025

Income statement

See full
Revenue$140.6M+18.5%
Gross profit$102.0M+29.5%
Operating income$37.2M+791%
Net income$41.1M+705%
EPS (diluted)$0.50+733%

Balance sheet

See full
Cash & equivalents$364.2M+51.4%
Total debt$39.7M-21.8%
Total equity$1.3B+11.4%
Total assets$1.4B+8.2%

Cash flow

See full
Operating cash flow$52.6M+114%
CapEx$3.8M-8.7%
Free cash flow$48.8M+139%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$3.33B+8.4%
Enterprise value$3B+4.3%
P/E50.2×-77.0×
P/S6.4×-0.4×

Profitability

See full
Gross margin70.1%+3.2pp
Operating margin11.2%+7.6pp
Net margin12.8%+7.4pp
FCF margin24.5%+10.2pp

Returns & leverage

See full
Return on equity5.3%+3.2pp
Debt / equity0×0.0×
Current ratio8.1×+3.4×

Segments

By segment

See full
Reportable Segment$140.6M+18.5%

By product

See full
Testing revenue$135.8M+21.1%

FAQ

When did Veracyte report Q4 2025 earnings?
Veracyte (VCYT) reported Q4 2025 earnings on February 25, 2026 after market close.
What were Veracyte's Q4 2025 revenue and EPS?
Veracyte reported revenue of $140.6M and eps of $0.53 for Q4 2025.
Did Veracyte beat estimates in Q4 2025?
Revenue beat the consensus estimate of $135.8M by $4.8M. EPS beat the consensus estimate of $0.41 by $0.12.
How did Veracyte's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 18.5% from $118.6M a year earlier and eps grew 47.2% from $0.36.
Where can I find Veracyte's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001384101-26-000008) and the 10-K periodic report (0001384101-26-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.